Mecillinam susceptibility in Victorian third generation cephalosporin-nonsusceptible Escherichia coli urinary isolates

Olenski, Maxwell; Jardine, Darren; Lorenzo, Yves S Poy; Crowe, Amy

doi:10.1016/j.pathol.2020.10.016

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A German study investigating resistance to mecillinam in E. coli isolates from urine specimens of adult primary care patients in Germany in 2019/2020 reported that 42 of 46 (91.3%) ESBL-producing isolates (80.4% of samples from female patients) were inhibited by mecillinam [ 30 ]. In an Australian study of urinary specimens with microscopy consistent with UTI, mecillinam susceptibility of E. coli resistant to third-generation cephalosporin was actually marginally higher than that reported for E. coli susceptible to third-generation cephalosporin (87.8% [86/98] vs 83.2% [84/101], respectively) [ 31 ].…”

Section: Literature Search Methodologymentioning

confidence: 99%

Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens

Lodise,

Kaye,

Santerre Henriksen

et al. 2024

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States (US). We performed a structured literature search to review the available evidence on susceptibility of common uUTI-causing uropathogens to mecillinam. Among 38 studies included in this literature review, susceptibility rates for Escherichia coli (E. coli) to mecillinam – including resistant phenotypes such as extended-spectrum β-lactamase–producing E. coli – exceed 90% in most studies. High rates of susceptibility were also reported among many other uropathogens including Klebsiella spp., Enterobacter spp., and Citrobacter spp. In the current prescribing climate within the US, pivmecillinam represents a viable first-line treatment option for patients with uUTI.

show abstract

Section: Literature Search Methodologymentioning

confidence: 99%

Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens

Lodise,

Kaye,

Santerre Henriksen

et al. 2024

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

Mecillinam susceptibility in Victorian third generation cephalosporin-nonsusceptible Escherichia coli urinary isolates

Abstract: Please cite this article as: Olenski M et al., Mecillinam susceptibility in Victorian third generation cephalosporin-nonsusceptible Escherichia coli urinary isolates, Pathology,

Cited by 1 publication

References 9 publications

Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens

Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens

Contact Info

Product

Resources

About